Cellectar Biosciences issued formal patent allowance from USPTO for CLR 1603
Cellectar Biosciences announces that the United States Patent and Trademark Office, or USPTO, has issued a formal patent allowance for CLR 1603, which covers method of use for the treatment of a variety of solid tumors and associated cancer stem cells using the company's phospholipid drug conjugate, or PDC, delivery platform technology with paclitaxel. This patent allowance follows the May 2016 issuance of the composition of matter patent for the same compound. CLR 1603 is a form of paclitaxel conjugated to the company's patented phospholipid drug conjugate delivery platform using a simple compound linker. The USPTO patent allowance covers method of use for breast, pancreatic, lung, colorectal and prostate cancers. The company expects the full patent to be granted by the end of 2016.